Citius Pharmaceuticals Reports $11.5 Million Net Loss and Zero Revenue for Quarter Ending March 31, 2025

Citius Pharmaceuticals, Inc. reported its financial results for the quarter ending March 31, 2025, revealing a net loss of $11.5 million, compared to a net loss of $8.5 million for the same period in 2024. The company did not generate any revenue during the quarter, maintaining a trend of zero revenue since its inception. Total operating expenses increased to $11.3 million from $11 million year-over-year, driven primarily by higher general and administrative costs associated with pre-launch activities for its oncology product, LYMPHIR. Research and development expenses rose slightly to $3.8 million, reflecting ongoing investments in product development.

In terms of financial position, Citius reported total assets of $121.5 million as of March 31, 2025, up from $116.7 million at the end of the previous fiscal year. The increase was primarily due to a rise in inventory, which grew to $15.3 million from $8.3 million, as the company prepares for the commercialization of LYMPHIR. However, total liabilities also increased significantly to $57.9 million, up from $42.5 million, largely due to a rise in accounts payable and accrued expenses. The company’s accumulated deficit reached $222.1 million, reflecting its ongoing operational losses.

Citius has made strategic moves to bolster its financial position, including a registered direct offering that raised approximately $1.7 million in early April 2025. This funding is expected to support operations through May 2025, but the company has acknowledged the need for substantial additional financing to continue its operations beyond this period. The company is actively exploring various capital-raising initiatives and has retained Jefferies LLC as its financial advisor to evaluate strategic alternatives.

Operationally, Citius is focused on the commercialization of LYMPHIR, which received FDA approval in August 2024. The company is also working on its other product candidates, including Mino-Lok, which is in the final stages of development. The company’s employee headcount has remained stable, with no significant changes reported in staffing levels. Citius continues to face challenges related to its ability to generate revenue and secure additional funding, which are critical for its future operations and growth.

Looking ahead, Citius Pharmaceuticals remains optimistic about the potential of LYMPHIR and its other product candidates. However, the company has cautioned that its ability to continue as a going concern is dependent on its success in raising additional capital and achieving commercial sales. The management has indicated that they are committed to executing their business strategy while navigating the complexities of the biopharmaceutical market.